Genenta Science S.p.A. Unsponsored ADR (
NASDAQ:GNTA -
Get Free Report) shares traded up 7.4% during mid-day trading on Wednesday . The stock traded as high as $4.50 and last traded at $3.78. 34,951 shares changed hands during mid-day trading, an increase of 500% from the average session volume of 5,830 shares. The stock had previously closed at $3.52.
Genenta Science Stock Up 7.4%
The firm has a 50 day simple moving average of $3.61 and a 200-day simple moving average of $3.87.
Hedge Funds Weigh In On Genenta Science
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new position in Genenta Science in the fourth quarter valued at about $46,000. Algebris UK Ltd boosted its holdings in Genenta Science by 122.2% in the first quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock worth $368,000 after acquiring an additional 55,000 shares in the last quarter. Finally, Allianz SE boosted its holdings in Genenta Science by 126.2% in the first quarter. Allianz SE now owns 233,550 shares of the company's stock worth $927,000 after acquiring an additional 130,300 shares in the last quarter. Hedge funds and other institutional investors own 15.13% of the company's stock.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
